CRWV vs TMO: Which Is the Better Buy?
Side-by-side comparison of CoreWeave, Inc. and Thermo Fisher Scientific Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-08-06.
CoreWeave, Inc. · Technology
$89.89
+24.6% upside to fair value
Med Conviction
Grade C+
VS
Thermo Fisher Scientific Inc. · Healthcare
$464.61
+7.2% upside to fair value
Grade A
High Quality
QuantHub Verdict
CRWV has more upside to fair value
(+24.6%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
CRWV |
TMO |
| Current Price |
$89.89 |
$464.61 |
| Fair Value Estimate |
$112.00 |
$498.27 |
| Upside to Fair Value |
+24.6%
|
+7.2%
|
| Market Cap |
$49.0B |
$172.7B |
| Forward P/E |
—
|
25.2x
|
| EV / EBITDA |
26.6x
|
19.1x
|
| Price / Sales |
7.9x
|
3.8x
|
| Price / FCF |
—
|
25.6x
|
| Revenue Growth YoY |
+111.6%
|
+6.2%
|
| Gross Margin |
69.4%
|
39.4%
|
| Operating Margin |
-2.6%
|
17.8%
|
| Return on Equity |
-33.5%
|
13.3%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
-21.6%
|
3.91%
|
| Analyst Consensus |
Buy
|
Strong Buy
|
Investment Thesis
CoreWeave is the leading neocloud, a GPU-specialized cloud infrastructure provider built to serve the compute-hungry demands of generative AI training and inference. Since its March 2025 IPO, revenue has scaled roughly 112% year over year to $2.08 billion in the first quarter of 2026, backed by a $99.4 billion contracted revenue backlog and marquee agreements with Microsoft, OpenAI, Meta, Anthrop…
Thermo Fisher Scientific is a leading healthcare company specializing in life science tools, diagnostics, and contract research and manufacturing services. It operates with a broad, multi-layered moat driven by scale, integration, and a long-tenured management team. The company exhibits solid fundamentals with a 13.3% ROE, 6.2% revenue growth, and 9.6% earnings growth in the most recent quarter. …
Accumulation Zones
| Metric |
CRWV |
TMO |
| Zone Low |
$84.00 |
$373.70 |
| Zone High |
$95.00 |
$423.53 |
| In Buy Zone? |
Yes
|
No
|